Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission ...

Before the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with ...

Many parents struggle with school lunches when their kids have multiple food allergies. The information may also help with ...

Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a ...

Diagnosing EoE can be tricky. There’s no single test, and symptoms like trouble swallowing, chest pain, and heartburn can mimic other conditions. Often, an endoscopy with biopsies, where a tiny tissue ...

A condition known as eosinophilic esophagitis, or EoE, affects one in 1,500 kids. They actually have an allergic reaction ...

The esophagus is the muscular tube that connects the mouth to the stomach and brings food into the body. In eosinophilic ...

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company leveraging its proprietary DiffuSphere technology to optimize drug delivery for applications with significant unmet need, ...

Fasenra was approved in 2017 but AZ came up short in its attempts to expand its label to chronic obstructive pulmonary ...

More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.

The FDA has approved Fasenra® (benralizumab) for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis.

CALY-002 is under development for the treatment of eosinophilic esophagitis, celiac disease and unspecified dermatological disorders. It is a fully-humanized monoclonal antibody also administered ...